Wednesday, December 28, 2011
There were many important arguments presented for or against screening for Alzheimer’s. You can listen to the podcast here. In particular, since there is no treatment available, it seems pointless to screen for Alzheimer’s. However, if you want to participate in clinical trials that might someday stop or reverse Alzheimer's disease, it's important to screen for it. Here is the map of current ongoing clinical trials on Alzheimer's disease.
Tuesday, August 9, 2011
Monday, May 2, 2011
From FDA news release: FDA approves new treatment for Type 2 diabetes. The clinical trial mentioned in this news release seems to be this one: Safety and Efficacy of BI 1356 as Monotherapy or in Combination in Type 2 DM.
According to MedlinePlus, Type 2 Diabetes is a chronic (lifelong) disease marked by high levels of sugar (glucose) in the blood. The chronic (lifelong) part makes it very attractive target for Pharma. There are currently more than 60 clinical trials for Diabetes Mellitus, Type 2 including new clinical trials that use linagliptin, and other dipeptidyl peptidase 4 (DPP4) inhibitors.
Tuesday, April 26, 2011
Video from 2011 NIH Pain Consortium Symposium are now online and this year it was entitled "Mechanisms and Management of Overlapping Chronic Pain and Associated Conditions." There were many interesting presentations about chronic pain and I highly recommend it. Here, I'll briefly mention presentation by Dr. Michael J. Iadarola about New Approaches to Analgesia Involving TRPV1 Agonists and Allosteric Modulators. It provides excellent background information about ongoing clinical trial for Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer. Resiniferatoxin (RTX) is a natural product extracted from cactus-like plants that grow in some parts of Africa. You can learn more about this clinical trial by watching this video (5:27:29).
Tuesday, March 29, 2011
If an FDA chemist can generate more than $3.6 million in illicit profits, I can imagine how much higher-ups can make. I won't be surprised if this is only the tip of the iceberg. The solution to this might be more transparent clinical trails, even when they are double-blinded. If public can have some input and it's not a simple go/no go decision, then FDA would be more trusted and leave less room for corruption. We definitely need next generation or 2.0 version of Open Clinical Trials.
Saturday, March 26, 2011
Since this drug is a monoclonal antibody, it can't be administered orally, otherwise it will be digested and won't reach its destination. In the clinical trial, it was done thought iv infusion over 90 minutes, every 3 weeks for 4 doses. The results of this clinical trial have been published in the New England Journal of Medicine - Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. It's interesting that in the patent for Ipilimumab it was used for reducing the incidence of adverse events related to immunotherapy.
I'll keep an eye on other trials that use Ipilimumab, including this one, where it's used for non small cell lung cancer.
Sunday, March 20, 2011
Sunday, February 6, 2011
|National Cancer Institute (NCI)||more than 526 trials|
|National Heart, Lung, and Blood Institute (NHLBI)||more than 162 trials|
|Pfizer||more than 140 trials|
The Incidence of Tobacco Taxation) not to mention $15.2 Billion collected by state governments annually. How much did we benefit from this remains to be answered.
As it stands now, the law requires mandatory registration and results reporting for certain clinical trials of drugs, biologics, and devices. Currently, ClinicalTrials.gov seems to be lacking any information that would be actually useful for patients. ClisMap blog is indented to provide patient centric information in this regard and we look forward for your comments and suggestions.